Company news
Delta-fly Pharma, Inc. (TSE:4598) news
Delta-fly Pharma, Inc. news releases on 6ix. Latest, Aug 31, 2026: Update on the Phase 2／3 Clinical Trial of DFP-17729
Press releases & updates
Update on the Phase 2／3 Clinical Trial of DFP-17729
August 31, 2026
Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax
March 3, 2025
Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax
December 9, 2024
Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
December 4, 2024
Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323
November 26, 2024
Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927
November 5, 2024
Delta-Fly Pharma Inc.: Phase I/II Study of DFP-10917 and Venetoclax in AML Patients Begins with Promising Initial Data
October 28, 2024
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients
September 10, 2024
Delta-Fly Pharma Inc. - Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
July 4, 2024
Delta-Fly Pharma Inc.: Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
July 3, 2024
Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax
April 8, 2024
Delta-Fly Pharma Inc.: FDA submission of the protocol of the Phase I/II study of DFP-10917 combined with Venetoclax (VTX) in the AML patients pretreated by VTX involved one regimen
March 11, 2024
Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting
February 7, 2024
Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323
February 2, 2024
Delta-Fly Pharma Inc.: Update on the R&D status of DFP-10917 and DFP-14927, a novel PEG Drug Conjugate, in the patients with R/R AML
January 5, 2024
Delta-Fly Pharma Inc.: Schedule for the Interim Analysis of the Phase 3 study of DFP-10917 in R/R AML
June 30, 2023
Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-10917
December 7, 2022
Delta-Fly Pharma, Inc. : Initiated Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927
November 26, 2019